Our partners are valued contributors in our global family of innovation. We are interested in partnering with organizations in the discovery, development, and commercialization of novel therapies within psychiatry and neurology. These collaborations enable us to maximize value for our patients, customers, and to support better health care.
Our Partnership Alliances
Sunovion’s collaboration with Urovant Sciences supports the commercialization of GEMTESA® (vibegron) tablets, an investigational medicine for the treatment of overactive bladder.
We are excited to work closely with our partners to launch Orgovyx™ (relugolix), a treatment for men with advanced prostate cancer.